mitomycin has been researched along with Germinoblastoma in 34 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antitumor effects of adoptive immunotherapy using LAK cells treated with sizofiran (SPG) following in vivo antigen sensitization with EL-4 lymphoma (EsLAK), comparing nonsensitized LAK cells (sLAK), were studied in mice with intraperitoneal implantation of EL-4 lymphoma." | 7.70 | Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran. ( Hashimoto, J; Kakuta, H; Kano, Y, 1998) |
| "Murine lymphoma cells (RDM4) were treated, in culture, with adriamycin (ADM) and with mitomycin C (Mit C) at various concentrations for 20 h." | 7.67 | Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with adriamycin. ( Leroux, JY; Mercier, G; Oth, D, 1986) |
| "Murine lymphoma cells (RDM4) were pretreated in culture, with Adriamycin (ADM) and with Mitomycin C (Mit C), at different concentrations, for 20 h and carefully washed." | 7.67 | Drug-concentration dependent sensitivity to lysis by antibody and complement, of adriamycin- or mitomycin-treated murine lymphoma cells. ( Leroux, JY; Mercier, G; Oth, D, 1987) |
| "Adriamycin and mitomycin C were previously found to modulate the sensitivity of lymphoma cells to lysis by certain effectors of immunity and this modulation was dependent on drug concentration." | 7.67 | Induction, by adriamycin and mitomycin C, of modifications in lipid composition, size distribution, membrane fluidity and permeability of cultured RDM4 lymphoma cells. ( Bégin, M; Bischoff, P; Bruneau, C; Leroux, JY; Mercier, G; Oth, D, 1987) |
| "Three patients with non-Hodgkin's lymphoma who relapsed and were considered to be resistant to standard chemotherapeutic agents including vinca alkaloids were treated with a vinca alkaloid combined with calcium antagonist, nicardipine." | 7.66 | [Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents]. ( Hattori, M; Honda, T; Sampi, K, 1983) |
| "The isobole method and the additive model were used to evaluate the combinations CHS 828-amiloride and CHS 828-mitomycin C (MMC) in the lymphoma cell line U-937 GTB and in primary cultures of tumour cells from patients." | 3.71 | Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients. ( Ekelund, S; Larsson, R; Nygren, P; Persson, I, 2002) |
| "The antitumor effects of adoptive immunotherapy using LAK cells treated with sizofiran (SPG) following in vivo antigen sensitization with EL-4 lymphoma (EsLAK), comparing nonsensitized LAK cells (sLAK), were studied in mice with intraperitoneal implantation of EL-4 lymphoma." | 3.70 | Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran. ( Hashimoto, J; Kakuta, H; Kano, Y, 1998) |
| "Murine lymphoma cells (RDM4) were treated, in culture, with adriamycin (ADM) and with mitomycin C (Mit C) at various concentrations for 20 h." | 3.67 | Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with adriamycin. ( Leroux, JY; Mercier, G; Oth, D, 1986) |
| "Murine lymphoma cells (RDM4) were pretreated in culture, with Adriamycin (ADM) and with Mitomycin C (Mit C), at different concentrations, for 20 h and carefully washed." | 3.67 | Drug-concentration dependent sensitivity to lysis by antibody and complement, of adriamycin- or mitomycin-treated murine lymphoma cells. ( Leroux, JY; Mercier, G; Oth, D, 1987) |
| "Adriamycin and mitomycin C were previously found to modulate the sensitivity of lymphoma cells to lysis by certain effectors of immunity and this modulation was dependent on drug concentration." | 3.67 | Induction, by adriamycin and mitomycin C, of modifications in lipid composition, size distribution, membrane fluidity and permeability of cultured RDM4 lymphoma cells. ( Bégin, M; Bischoff, P; Bruneau, C; Leroux, JY; Mercier, G; Oth, D, 1987) |
| "Three patients with non-Hodgkin's lymphoma who relapsed and were considered to be resistant to standard chemotherapeutic agents including vinca alkaloids were treated with a vinca alkaloid combined with calcium antagonist, nicardipine." | 3.66 | [Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents]. ( Hattori, M; Honda, T; Sampi, K, 1983) |
| "Aneuploidy was confirmed using G-banding combined with chromosome painting analysis for mutants showing LOH at every microsatellite marker on chromosome 11." | 1.35 | The mouse lymphoma assay detects recombination, deletion, and aneuploidy. ( Chen, L; Chen, T; Honma, M; Mei, N; Moore, MM; Sawyer, JR; Wang, J, 2009) |
| "Two lymphomas were found in, and isolated from A (H-2a) mice in which permanent transplantation tolerance was induced to CBA (H-2k) histocompatibility antigens by the neonatal injection of (CBAxA)F1 spleen cells." | 1.29 | MHC-specific graft-protective and delayed-type hypersensitivity (DTH) suppressive activity of a CD4+ CD8+, alpha beta T cell receptor (TCR) positive lymphoma isolated from a tolerant mouse. ( Baranyi, L; Benner, R; Jánossy, T; Knulst, AC; Végh, P; Vizler, C, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (50.00) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 9 (26.47) | 29.6817 |
| 2010's | 2 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El Ghamrasni, S | 1 |
| Cardoso, R | 2 |
| Halaby, MJ | 1 |
| Zeegers, D | 1 |
| Harding, S | 1 |
| Kumareswaran, R | 1 |
| Yavorska, T | 1 |
| Chami, N | 1 |
| Jurisicova, A | 1 |
| Sanchez, O | 2 |
| Hande, MP | 3 |
| Bristow, R | 1 |
| Hakem, R | 3 |
| Hakem, A | 2 |
| Matsuzaki, K | 1 |
| Borel, V | 1 |
| Adelman, CA | 1 |
| Schindler, D | 1 |
| Boulton, SJ | 1 |
| Xiao, H | 1 |
| Zhang, K | 1 |
| Xia, B | 1 |
| Wang, J | 1 |
| Sawyer, JR | 1 |
| Chen, L | 1 |
| Chen, T | 1 |
| Honma, M | 2 |
| Mei, N | 1 |
| Moore, MM | 1 |
| Ekelund, S | 1 |
| Persson, I | 1 |
| Larsson, R | 1 |
| Nygren, P | 1 |
| ONO, S | 1 |
| YAMADA, H | 1 |
| KUNI, A | 1 |
| TANIDA, T | 1 |
| SOKOLOFF, B | 1 |
| MCCONNELL, B | 1 |
| ISHIBASHI, Y | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| NGU, VA | 1 |
| McPherson, JP | 1 |
| Lemmers, B | 1 |
| Chahwan, R | 1 |
| Pamidi, A | 2 |
| Migon, E | 1 |
| Matysiak-Zablocki, E | 2 |
| Moynahan, ME | 1 |
| Essers, J | 1 |
| Hanada, K | 1 |
| Poonepalli, A | 2 |
| Sanchez-Sweatman, O | 1 |
| Khokha, R | 1 |
| Kanaar, R | 1 |
| Jasin, M | 1 |
| Shuai, PQ | 1 |
| Zhang, LS | 2 |
| Wang, YJ | 1 |
| Shima, N | 1 |
| Munroe, RJ | 1 |
| Schimenti, JC | 1 |
| Henson, SE | 1 |
| Tsai, SC | 1 |
| Malone, CS | 1 |
| Soghomonian, SV | 1 |
| Ouyang, Y | 1 |
| Wall, R | 1 |
| Marahrens, Y | 1 |
| Teitell, MA | 1 |
| Tamblyn, L | 1 |
| Perez-Ordonez, B | 1 |
| Takeuchi, S | 1 |
| Akahoshi, Y | 1 |
| Kasai, C | 1 |
| Nishimoto, Y | 1 |
| Tsuru, S | 1 |
| Nomoto, K | 1 |
| Kasajima, T | 1 |
| Yamakawa, M | 1 |
| Maeda, K | 1 |
| Matsuda, M | 1 |
| Dobashi, M | 1 |
| Imai, Y | 1 |
| Honda, T | 1 |
| Sampi, K | 1 |
| Hattori, M | 1 |
| Hayashi, M | 1 |
| Suzuki, T | 1 |
| Matsuoka, A | 1 |
| Sofuni, T | 1 |
| Jánossy, T | 1 |
| Baranyi, L | 1 |
| Knulst, AC | 1 |
| Vizler, C | 1 |
| Benner, R | 1 |
| Végh, P | 1 |
| Begleiter, A | 1 |
| Leith, MK | 1 |
| Curphey, TJ | 1 |
| Kano, Y | 1 |
| Kakuta, H | 1 |
| Hashimoto, J | 1 |
| Das, A | 1 |
| Saxena, RK | 1 |
| Saito, T | 1 |
| Otaka, T | 1 |
| Sato, H | 1 |
| Rosselli, F | 1 |
| Moustacchi, E | 1 |
| Tsuji, M | 1 |
| Itoh, Y | 1 |
| Fukada, H | 1 |
| Mori, H | 1 |
| Sugimori, K | 1 |
| Ohyabu, H | 1 |
| Kageyama, T | 1 |
| Dillman, RO | 1 |
| Johnson, DE | 1 |
| Ogden, J | 1 |
| Beidler, D | 1 |
| Leroux, JY | 3 |
| Mercier, G | 3 |
| Oth, D | 3 |
| Bégin, M | 1 |
| Bischoff, P | 1 |
| Bruneau, C | 1 |
| Nishimura, T | 1 |
| Uchiyama, Y | 1 |
| Hashimoto, Y | 1 |
| Moriya, Y | 1 |
| Koyama, Y | 1 |
| Minato, K | 1 |
| Shimoyama, M | 1 |
| Hirota, T | 1 |
| Itabashi, M | 1 |
34 other studies available for mitomycin and Germinoblastoma
| Article | Year |
|---|---|
Cooperation of Blm and Mus81 in development, fertility, genomic integrity and cancer suppression.
Topics: Animals; Cell Transformation, Neoplastic; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA E | 2015 |
FANCJ suppresses microsatellite instability and lymphomagenesis independent of the Fanconi anemia pathway.
Topics: Animals; Antineoplastic Agents; Basic-Leucine Zipper Transcription Factors; Camptothecin; Cell Line; | 2015 |
[Search for Fanconi anemia/BRCA pathway defects in lymphoma cell lines].
Topics: Animals; Antibiotics, Antineoplastic; Base Sequence; BRCA2 Protein; Cell Cycle; Cell Line, Tumor; Ce | 2008 |
The mouse lymphoma assay detects recombination, deletion, and aneuploidy.
Topics: Aneuploidy; Animals; Antimetabolites; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Prol | 2009 |
Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.
Topics: Amiloride; Antibiotics, Antineoplastic; Cyanides; Diuretics; Drug Interactions; Guanidines; Humans; | 2002 |
[On the medical therapy of malignant lymphoma].
Topics: Antineoplastic Agents; Azaguanine; Cortisone; Cyclophosphamide; Humans; Lymphoma; Mercaptopurine; Mi | 1962 |
[HISTOPATHOLOGICAL EFFECTS OF ANTINEOPLASTIC AGENTS ON MALIGNANT LYMPHOMA].
Topics: Antineoplastic Agents; Child; Chlorambucil; Cyclophosphamide; Dactinomycin; Geriatrics; Hodgkin Dise | 1964 |
HOST DEFENCE AND CHEMOTHERAPY IN EXPERIMENTAL CANCER.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Dactinomycin; Flavonoids; Lymphoma; Lymphoma, | 1964 |
CANCER CHEMOTHERAPY (MITOMYCIN-C) FOLLOWED BY BONE MARROW TRANSPLANTATION.
Topics: Bone Marrow Transplantation; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Bronchogenic; Choriocarci | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
THE CHEMOTHERAPY OF CANCER. (A PRELIMINARY REPORT OF ITS SCOPE IN WEST AFRICA).
Topics: Africa; Africa, Western; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Antineoplastic A | 1964 |
Involvement of mammalian Mus81 in genome integrity and tumor suppression.
Topics: Alleles; Animals; Chromosome Aberrations; DNA Damage; DNA-Binding Proteins; Embryo, Mammalian; Embry | 2004 |
[TK locus mutation assay: comparison of L5178Y and TK6 cell lines].
Topics: Animals; Cell Line, Tumor; Ethyl Methanesulfonate; Humans; Leukemia L5178; Lymphoma; Methyl Methanes | 2004 |
The mouse genomic instability mutation chaos1 is an allele of Polq that exhibits genetic interaction with Atm.
Topics: Alleles; Animals; Ataxia Telangiectasia Mutated Proteins; Blotting, Northern; Cell Cycle Proteins; C | 2004 |
Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks.
Topics: Blotting, Northern; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromosome Break | 2006 |
Functional interplay of p53 and Mus81 in DNA damage responses and cancer.
Topics: Animals; B-Lymphocytes; Cell Differentiation; Cell Growth Processes; DNA; DNA Damage; DNA-Binding Pr | 2007 |
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1984 |
Effects of PSK on specific tumor immunity to syngeneic tumor cells.
Topics: Animals; Ascitic Fluid; Cytotoxicity, Immunologic; Immunization; Lymphoma; Male; Mice; Mice, Inbred | 1983 |
[Effect of cepharanthin on peripheral leukocytopenia caused by antineoplastic agents].
Topics: Alkaloids; Animals; Benzylisoquinolines; Fluorouracil; Leukopenia; Lymphoma; Mice; Mice, Inbred Stra | 1983 |
[Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Drug Therapy, Combination; Fe | 1983 |
A comparative study of TK6 human lymphoblastoid and L5178Y mouse lymphoma cell lines in the in vitro micronucleus test.
Topics: Animals; B-Lymphocytes; Cell Line; Cell Survival; Demecolcine; Ethyl Methanesulfonate; Humans; Leuke | 1995 |
MHC-specific graft-protective and delayed-type hypersensitivity (DTH) suppressive activity of a CD4+ CD8+, alpha beta T cell receptor (TCR) positive lymphoma isolated from a tolerant mouse.
Topics: Animals; Animals, Newborn; CD4 Antigens; CD8 Antigens; Cell Division; Flow Cytometry; Fluorescent An | 1993 |
Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.
Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Enzyme Induction; Indolequinones; Ind | 1996 |
Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran.
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Age | 1998 |
Abrogation of tumor induced Ly49 expression on mouse spleen cells by mitomycin C.
Topics: Animals; Antigens, Ly; Cell Division; Down-Regulation; Fixatives; Formaldehyde; Immunosuppressive Ag | 2001 |
[Nephrotic syndrome associated with neoplasms and malignant lymphoma].
Topics: Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphoma; Male; Middle Aged; Mitomycin; | 1992 |
Cocultivation of Fanconi anemia cells and of mouse lymphoma mutants leads to interspecies complementation of chromosomal hypersensitivity to DNA cross-linking agents.
Topics: Anemia, Aplastic; Animals; Cell Division; Cells, Cultured; Chromosome Aberrations; Fanconi Anemia; G | 1990 |
[An autopsy study of immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma in a patient previously treated with chemotherapy in colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1989 |
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cell Line; Cytotoxicity, Immunologic; Daunorubi | 1989 |
Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with adriamycin.
Topics: Animals; Cell Line; Cytotoxicity, Immunologic; Doxorubicin; Kinetics; Lymphoma; Mice; Mice, Inbred A | 1986 |
Drug-concentration dependent sensitivity to lysis by antibody and complement, of adriamycin- or mitomycin-treated murine lymphoma cells.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Cell Line; Complement System Proteins; Dose-Response | 1987 |
Induction, by adriamycin and mitomycin C, of modifications in lipid composition, size distribution, membrane fluidity and permeability of cultured RDM4 lymphoma cells.
Topics: Animals; Cell Line; Cell Membrane; Cell Membrane Permeability; Cell Survival; DNA Replication; Doxor | 1987 |
In vivo generation of lymphokine-activated killer cells by sensitization with interleukin 2-producing syngeneic T-lymphoma cells.
Topics: Animals; Cell Line; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Lymphoma; Mice; Mic | 1988 |
[Coexisting malignant lymphoma and advanced adenocarcinoma of the colon--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosphamide; | 1985 |